Geron’s resurgence might have been short-lived
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a look at why some wished-for gene therapies failed to make a splash when they came true and the words of ALS patients in the aftermath of another crushing setback.
Read Original Article: Geron’s resurgence might have been short-lived »
